UroGen Pharma (URGN) vs Vera Therapeutics (VERA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
UroGen Pharma (URGN) has outperformed Vera Therapeutics (VERA) over the past year, gaining 113.4% versus a loss of 2.5%. Over five years, URGN leads with a +117.3% price change compared with +98.1% for VERA. Vera Therapeutics is the larger company by market cap ($2.14 billion vs $1.82 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | URGN | VERA |
|---|---|---|
| Share price | $37.27 | $29.71 |
| Market cap | $1.82B | $2.14B |
| 1-day change | +0.77% | -0.07% |
| YTD return | +57.90% | -41.29% |
| 1-year return | +113.39% | -2.52% |
| 5-year return | +117.27% | +98.07% |
| Forward P/E | 13.34 | — |
| EPS (TTM) | $-1.97 | $-5.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $109.79M | — |
| Revenue growth (YoY) | +21.45% | — |
| Net income (latest FY) | $-153.49M | $-299.62M |
| Gross margin | 88.66% | — |
| Operating margin | -113.73% | — |
| Net margin | -139.81% | — |
| 52-week high | $50.81 | $56.05 |
| 52-week low | $15.86 | $23.05 |
| Distance from 52-week high | -26.66% | -46.99% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +61.01% | +160.85% |
| Average volume | 849.01K | 2.21M |
| Shares outstanding | 48.88M | 72.06M |
| Employees | 300 | 361 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- URGN has outperformed VERA by 115.9 percentage points over the past year.
About UroGen Pharma
URGN stock →UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees
About Vera Therapeutics
VERA stock →Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 361 employees
URGN vs VERA FAQ
Which is bigger, UroGen Pharma or Vera Therapeutics?
Vera Therapeutics (VERA) is larger, with a market capitalization of $2.14B compared with $1.82B for UroGen Pharma (URGN).
Which stock has performed better over the past year, URGN or VERA?
URGN returned +113.39% over the past 12 months, compared with -2.52% for VERA (price return, excluding dividends). Past performance does not predict future results.
Are UroGen Pharma and Vera Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.